Physicians' Academy for Cardiovascular Education

PCSK9 inhibition works, but you can’t force biology

Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Changing therapeutic behaviour after FOURIER

Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA

Initiating digoxin in AF patients associated with early hazard of sudden death

Mar. 19, 2017 - ACC 2017, Washington, DC, USA - Dr. Renato Lopes

The implications of PCSK9 outcome trials for GPs

Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

PCI-registry-based trial shows that IFR is non-inferior to FFR, with reduced discomfort and stenting

Mar. 20, 2017 - Matthias Götberg - Lund University, Sweden

Factor Xa inhibitor vs. aspirin in extended phase of prevention recurrent VTE

Mar. 18, 2017 - ACC 2017, Washington, DC, USA - Dr. Philip S. Wells - Ottawa, ON, Canada

E-counselling improves adherence in hypertensives

Mar. 21, 2017 - Dr. Rob Nolan, Toronto, ONT, Canada

PCSK9 inhibitors: From bench to bedside

Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

Troponin is an independent predictor of CV events at non-cardiac surgery

Mar. 21, 2017 - Dr. P.J. Devereaux - Hamilton, ONT, Canada

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 outcome trials: The results put into perspective of other clinical developments

Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA

LDL lowering for CVD prevention: From hypothesis to axiom

Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

Mar. 17, 2017

CV outcomes with a PCSK9 inhibitor: FOURIER study

Mar. 16, 2017

PCSK9 inhibition works, but you can’t force biology

Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA
Prof. Wouter Jukema summarizes the results from FOURIER and SPIRE into the message that PCSK9 inhibition works, it is safe, and you cannot force biology

PCSK9 Expert Opinions Prof. Wouter Jukema summarizes the results from FOURIER and SPIRE into the message that PCSK9 inhibition works – even lower is even better; it is safe, and you cannot force biology – it takes a long time to get atherosclerosis, so it will also take some time to get rid of it.

Identification of patients who will benefit is important after FOURIER

Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA
Prof. Ulf Landmesser states that the results of both FOURIER and SPIRE fit into the concept that lowering LDL to very low levels results in a reduction in CV events

PCSK9 Expert Opinions Prof. Ulf Landmesser states that the results of both FOURIER and SPIRE fit into the concept that lowering LDL to very low levels results in a reduction in CV events

Landmark study with PCSK9 inhibitor will change clinical practice

Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA
According to prof. Eric Bruckert, FOURIER is a landmark study that will change clinical practice, especially for patients with the highest risk.

PCSK9 Expert Opinions According to prof. Eric Bruckert, FOURIER is a landmark study that will change clinical practice, especially for patients with the highest risk.

Changing therapeutic behaviour after FOURIER

Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA
Prof. Wolfgang Koenig argues that PCSK9 inhibitors will be drugs of great value in the future, especially for patients with FH and statin intolerance.

PCSK9 Expert Opinions Prof. Wolfgang Koenig describes the results of FOURIER and SPIRE. He expects that PCSK9 inhibitors will be drugs of great value in the future, especially for patients with FH and statin intolerance.

Initiating digoxin in AF patients associated with early hazard of sudden death

Mar. 19, 2017 - ACC 2017, Washington, DC, USA - Dr. Renato Lopes
A substudy of ARISTOTLE showed that new users of digoxin had a four-fold risk of sudden death, and higher plasma digoxin levels were associated with higher risk, also in AF patients who used digoxin at baseline.

ACC 2017 A substudy of ARISTOTLE showed that new users of digoxin had a four-fold risk of sudden death, and higher plasma digoxin levels were associated with higher risk, also in AF patients who used digoxin at baseline.

The implications of PCSK9 outcome trials for GPs

Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA
Prof. Richard Hobbs states that PCSK9 inhibition reduces endpoints that are important and expensive both for individuals and for health systems.

PCSK9 Expert Opinions Prof. Richard Hobbs states that recent data from FOURIER show that effective medical treatment to lower LDL-c reduces endpoints that are important and expensive both for individuals and for health systems.

PCI-registry-based trial shows that IFR is non-inferior to FFR, with reduced discomfort and stenting

Mar. 20, 2017 - Matthias Götberg - Lund University, Sweden
Matthias Götberg summarises the advantages of the SCAAR-registry-based trial design of the randomised IFR-SWEDEHEART trial and shares the results of this study into clinical outcomes after IFR as compared with FFR.

ACC 2017 Matthias Götberg summarises the advantages of the registry-based trial design of the randomised IFR-SWEDEHEART trial and shares the results of this study into clinical outcomes after IFR as compared with FFR.

Factor Xa inhibitor vs. aspirin in extended phase of prevention recurrent VTE

Mar. 18, 2017 - ACC 2017, Washington, DC, USA - Dr. Philip S. Wells - Ottawa, ON, Canada
**ACC 2017** Dr. Philip Wells presented the EINSTEIN-CHOICE study, in which two doses of the NOAC rivaroxaban were shown to be more effective than aspirin in the prevention of recurrent VTE in the long run.

ACC 2017 Dr. Philip Wells presented the EINSTEIN-CHOICE study, in which two doses rivaroxaban were shown to be more effective than aspirin in the prevention of recurrent VTE in the long run.

E-counselling improves adherence in hypertensives

Mar. 21, 2017 - Dr. Rob Nolan, Toronto, ONT, Canada
 Dr. Rob Nolan presented the results of the double-blind randomised controlled REACH study, in which multi-medial e-counselling significantly improved antihypertensive therapy adherence, and it lowered blood pressure.

ACC 2017 Dr. Rob Nolan presented the results of the REACH study, in which multi-medial e-counselling significantly improved antihypertensive therapy adherence, and it lowered blood pressure.

PCSK9 inhibitors: From bench to bedside

Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA
Prof. Gilles Lambert describes the development since the discovery in 2002 of PCSK9 until the results of outcome trials with a PCSK9 inhibitor in 2017.

PCSK9 Expert Opinions Prof. Gilles Lambert describes the development of PCSK9 inhibitors since the discovery in 2002 of PCSK9 as a circulating protein targeting the LDL receptor for degradation. Now in 2017, results of outcome trials with a PCSK9 inhibitor are available.

Troponin is an independent predictor of CV events at non-cardiac surgery

Mar. 21, 2017 - Dr. P.J. Devereaux - Hamilton, ONT, Canada
ACC 2017 Dr. P.J. Devereaux presented the VISION study, in which hs-TNT turned out to be an independent predictor of CV events and mortality around non-cardiac surgery. A post-operative peak value was determined that indicates increased risk.

ACC 2017 Dr. P.J. Devereaux presented the VISION study, in which hs-TNT turned out to be an independent predictor of CV events and mortality around non-cardiac surgery. A post-operative peak value was determined that indicates increased risk.

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA
Prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.

PCSK9 Expert Opinions By combining all recent insights on treatment with PCSK9 inhibitors, prof. Stephen Nicholls argues that the PCSK9 outcome trials reinforce the concept that patients with high CV risk may benefit from PCSK9 inhibiting treatment.